Lutetium (177Lu) chloride Billev (previously Illuzyce)


lutetium (177Lu) chloride

This medicine is authorised for use in the European Union.


Lutetium (177Lu) chloride Billev is a solution containing a radioactive form of lutetium (177lu) that is used for radiolabelling other medicines. Radiolabelling is a technique where a substance is labelled with a radioactive compound. Once the substance is radiolabelled with Lutetium (177Lu) chloride Billev, it then carries the radioactivity to where it is needed in the body (for example, the site of a tumour).

Lutetium (177Lu) chloride Billev is used to radiolabel medicines that have been specifically developed for use with lutetium (177lu) chloride.

Lutetium (177Lu) chloride Billev contains the active substance lutetium (177lu) chloride.

This EPAR was last updated on 08/12/2022

Authorisation details

Product details
Lutetium (177Lu) chloride Billev (previously Illuzyce)
Agency product number
Active substance
lutetium (177Lu) chloride
International non-proprietary name (INN) or common name
lutetium (177Lu) chloride
Therapeutic area (MeSH)
Radionuclide Imaging
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Billev Pharma Aps
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Slotsmarken 10
2970 Hoersholm

Product information

14/11/2022 Lutetium (177Lu) chloride Billev (previously Illuzyce) - EMEA/H/C/005859 - IAIN/0001/G

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Therapeutic radiopharmaceuticals

Therapeutic indication

Lutetium (177Lu) chloride Billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. It is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177Lu) chloride.

Assessment history

How useful was this page?

Add your rating